54 related articles for article (PubMed ID: 18615564)
1. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells.
Fabbri F; Amadori D; Carloni S; Brigliadori G; Tesei A; Ulivi P; Rosetti M; Vannini I; Arienti C; Zoli W; Silvestrini R
J Cell Physiol; 2008 Nov; 217(2):494-501. PubMed ID: 18615564
[TBL] [Abstract][Full Text] [Related]
2. A link between mitotic defects and mitotic catastrophe: detection and cell fate.
Sazonova EV; Petrichuk SV; Kopeina GS; Zhivotovsky B
Biol Direct; 2021 Dec; 16(1):25. PubMed ID: 34886882
[TBL] [Abstract][Full Text] [Related]
3. Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells.
Clementi L; Sabetta S; Zelli V; Compagnoni C; Tessitore A; Mattei V; Angelucci A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7689-7701. PubMed ID: 37000265
[TBL] [Abstract][Full Text] [Related]
4. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
[TBL] [Abstract][Full Text] [Related]
5. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Eberlein C; Williamson SC; Hopcroft L; Ros S; Moss JI; Kerr J; van Weerden WM; de Bruin EC; Dunn S; Willis B; Ross SJ; Rooney C; Barry ST
Br J Cancer; 2024 May; 130(8):1377-1387. PubMed ID: 38396173
[TBL] [Abstract][Full Text] [Related]
6. GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer.
Wan L; Liu Y; Liu R; Mao W
Cancer Cell Int; 2023 Oct; 23(1):255. PubMed ID: 37904122
[TBL] [Abstract][Full Text] [Related]
7. Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment.
Vergote I; Macarulla T; Hirsch FR; Hagemann C; Miller DS
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765594
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939.
Pudova E; Kobelyatskaya A; Katunina I; Snezhkina A; Nyushko K; Fedorova M; Pavlov V; Bulavkina E; Dalina A; Tkachev S; Alekseev B; Krasnov G; Volodin V; Kudryavtseva A
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361635
[TBL] [Abstract][Full Text] [Related]
9. Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer.
Nasser NJ
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454866
[TBL] [Abstract][Full Text] [Related]
10. Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1-6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare.
Nasser NJ; Sun K; Scanlon KM; Mishra MV; Molitoris JK
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205611
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the cytotoxicity induced by didocosahexaenoin, an omega 3 derivative, in human prostate carcinoma cell lines.
Robinson GF; Sooda KK; Phillips RM; Allison SJ; Javid FA
Curr Res Pharmacol Drug Discov; 2022; 3():100085. PubMed ID: 35112078
[TBL] [Abstract][Full Text] [Related]
12. Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis.
Kim SC; Lee WH; Kim SH; Abdulkhayevich AA; Park JW; Kim YM; Moon KH; Lee SH; Park S
Investig Clin Urol; 2021 Jul; 62(4):485-495. PubMed ID: 34190439
[TBL] [Abstract][Full Text] [Related]
13. Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer.
Liu RJ; Li SY; Liu LQ; Xu B; Chen M
Bioengineered; 2021 Dec; 12(1):2377-2388. PubMed ID: 34077304
[TBL] [Abstract][Full Text] [Related]
14. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
Qiu X; Wang W; Li B; Cheng B; Lin K; Bai J; Li H; Yang G
BMC Cancer; 2019 Jan; 19(1):27. PubMed ID: 30621625
[TBL] [Abstract][Full Text] [Related]
15. The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells.
Mansour M; van Ginkel S; Dennis JC; Mason B; Elhussin I; Abbott K; Pondugula SR; Samuel T; Morrison E
J Cancer; 2018; 9(23):4536-4546. PubMed ID: 30519360
[No Abstract] [Full Text] [Related]
16. Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells.
Cristofani R; Montagnani Marelli M; Cicardi ME; Fontana F; Marzagalli M; Limonta P; Poletti A; Moretti RM
Cell Death Dis; 2018 Aug; 9(9):889. PubMed ID: 30166521
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-κB Activation.
Pan Y; Lin S; Xing R; Zhu M; Lin B; Cui J; Li W; Gao J; Shen L; Zhao Y; Guo M; Wang JM; Huang J; Lu Y
Antioxid Redox Signal; 2016 May; 24(15):839-54. PubMed ID: 26801633
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells.
Yoshino Y; Ishioka C
Sci Rep; 2015 Aug; 5():13249. PubMed ID: 26292722
[TBL] [Abstract][Full Text] [Related]
20. The role of individual caspases in cell death induction by taxanes in breast cancer cells.
Jelínek M; Balušíková K; Schmiedlová M; Němcová-Fürstová V; Šrámek J; Stančíková J; Zanardi I; Ojima I; Kovář J
Cancer Cell Int; 2015; 15(1):8. PubMed ID: 25685064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
